Chinese cell therapy biotech developing TIL therapies raises $60M Series B
Grit Biotechnology said Friday that it closed a Series B, raising more than $60 million from several Chinese investors.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
